Estrella Immunopharma, Inc. (ESLA): Nasdaq/NYSE listing notice — TradeUP Acquisition receives Nasdaq extension to Oct 16, 2023 for Public Holder Rule compliance

Estrella Immunopharma, Inc.

Nasdaq granted extension until October 16, 2023 to regain compliance with Listing Rule 5550(a)(3).
Company had previously disclosed non-compliance and submitted a compliance plan on June 5, 2023.
Failure to regain compliance by deadline may result in delisting from Nasdaq.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(3)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5550(a)(3)

Exact text from the filing

June 22, 2023, TradeUP Acquisition Corp. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Markets (“Nasdaq”) stating that the Nasdaq Staff had determined to grant the Company an extension of time through October 16, 2023 to regain compliance with Listing Rule 5550(a)(3) (the “Public Holder Rule”). As previously disclosed, the Company had received a separate written notice from Nasdaq stating that the Company did not meet the requirements of the Public Holder Rule. The Company submitted its plan of compliance on June 5, 2023 according

View on SEC.gov

Browse all listing & compliance notices →

Estrella Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001575872-23-001032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.